In line with this, chronic pharmacological inhibition of TRPA1 channels has positive effects on disease outcomes in the same AD model by normalizing spine density and maturation and reducing astrocyte Ca2+ hyperactivity (Paumier et al. (2022) [36]). This evidence concerns the gene TRPA1 and Alzheimer disease.